ATE551432T1 - Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege - Google Patents

Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege

Info

Publication number
ATE551432T1
ATE551432T1 AT05762518T AT05762518T ATE551432T1 AT E551432 T1 ATE551432 T1 AT E551432T1 AT 05762518 T AT05762518 T AT 05762518T AT 05762518 T AT05762518 T AT 05762518T AT E551432 T1 ATE551432 T1 AT E551432T1
Authority
AT
Austria
Prior art keywords
depressive disease
manic
genes
expressed differently
disease
Prior art date
Application number
AT05762518T
Other languages
English (en)
Inventor
Huda Akil
Jr William E Bunney
Prabhakara V Choudary
Simon J Evans
Edward G Jones
Jun Li
Juan F Lopez
David M Lyons
Margherita Molnar
Richard M Myers
Alan F Schatzberg
Richard Stein
Robert C Thompson
Hiroaki Tomita
Marquis P Vawter
Stanley J Watson
Cortney A Turner
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE551432T1 publication Critical patent/ATE551432T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
AT05762518T 2004-06-21 2005-06-21 Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege ATE551432T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58199804P 2004-06-21 2004-06-21
US62125204P 2004-10-22 2004-10-22
US66729605P 2005-03-31 2005-03-31
PCT/US2005/022111 WO2006002262A2 (en) 2004-06-21 2005-06-21 Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder

Publications (1)

Publication Number Publication Date
ATE551432T1 true ATE551432T1 (de) 2012-04-15

Family

ID=35782328

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05762518T ATE551432T1 (de) 2004-06-21 2005-06-21 Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege

Country Status (8)

Country Link
US (3) US8415298B2 (de)
EP (2) EP2453024B1 (de)
AT (1) ATE551432T1 (de)
AU (1) AU2005258161B2 (de)
CA (1) CA2571243A1 (de)
DK (2) DK2453024T3 (de)
ES (1) ES2660765T3 (de)
WO (1) WO2006002262A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291720A1 (en) * 2002-11-01 2004-06-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
WO2007136797A1 (en) * 2006-05-18 2007-11-29 The Mclean Hospital Corporation Methods for diagnosis and prognosis of psychotic disorders
WO2008124428A1 (en) * 2007-04-03 2008-10-16 Indiana University Research And Technology Corporation Blood biomarkers for mood disorders
US20100248230A1 (en) * 2007-04-14 2010-09-30 Schlaak Joerg Friedrich Novel medical diagnostic method and therapy in the context of interfreon-stimulated genes that induce depression
WO2008144371A1 (en) * 2007-05-16 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosing suicidal tendencies
WO2009011911A2 (en) * 2007-07-18 2009-01-22 The Johns Hopkins University Methods of detecting prostate cancer
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
CA2704428C (en) * 2007-11-02 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Fgf9-related methods for treating anxiety
EP2570498A3 (de) * 2008-01-02 2013-03-27 Suregene Llc Genetische Marker für Geisteskrankheiten
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
CA2728171A1 (en) * 2008-08-27 2010-03-04 H. Lundbeck A/S System and methods for measuring biomarker profiles
CA2743542A1 (en) * 2008-11-12 2010-05-20 University Of Utah Research Foundation Autism associated genetic markers
JP2012511895A (ja) * 2008-11-14 2012-05-31 ザ チルドレンズ ホスピタル オブ フィラデルフィア ヒト認知の原因となる遺伝子変異体及び診断標的及び治療標的としてのそれらを使用する方法
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201204816D0 (en) * 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders
WO2014133707A1 (en) * 2013-03-01 2014-09-04 Psychnostics, Llc Genes expressed in mental illness and mood disorders
US11235020B2 (en) * 2013-03-13 2022-02-01 Abraham Palmer Methods and compositions for inhibiting glyoxalase 1 (GLO1)
US20160209428A1 (en) * 2013-08-21 2016-07-21 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system
WO2015129324A1 (ja) * 2014-02-26 2015-09-03 国立大学法人徳島大学 精神疾患マーカーおよびその用途
CN109022486B (zh) * 2018-09-20 2021-09-07 河北医科大学第二医院 一种癫痫动物模型的构建方法
EP3819387A1 (de) * 2019-11-08 2021-05-12 Alcediag Differentialdiagnose von bipolarer störung und unipolarer depression durch blut-rna-bearbeitungsbiomarker
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
CN116904578B (zh) * 2023-07-21 2024-03-15 武汉市精神卫生中心 线粒体差异化表达特征基因在制备重度抑郁症诊断剂中的应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US6187752B1 (en) 1988-03-07 2001-02-13 E.R. Squibb & Sons, Inc. Method for treating schizophrenia employing an ace inhibitor
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
CA2095256A1 (en) 1990-10-31 1992-05-01 Brad Guild Retroviral vectors useful for gene therapy
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
ES2061380B1 (es) 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
PT1921169E (pt) 1993-11-12 2012-05-23 Phri Properties Inc Sondas de hibridação para detecção de ácidos nucleicos, troncos universais, métodos e estojos
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6024734A (en) 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US20030191061A1 (en) 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
EP0836380B1 (de) 1995-06-12 2002-02-27 Yeda Research And Development Co. Ltd. Fgf9 als spezifischer ligand für fgfr3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
JP3439221B2 (ja) 1995-12-18 2003-08-25 ワシントン ユニヴァーシティ 蛍光共鳴エネルギー移動を利用する核酸分析方法
JP2000507939A (ja) * 1996-03-22 2000-06-27 ザ ジェネラル ホスピタル コーポレーション 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
US6117890A (en) 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
JP2001506580A (ja) 1996-12-24 2001-05-22 藤沢薬品工業株式会社 アミノピペラジン誘導体の新規用途
EP1009403A4 (de) 1997-04-11 2002-08-28 Lilly Co Eli Verfahren zur behandlung von schizophrenie
DE69825605T2 (de) 1997-05-29 2005-09-15 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
CA2216686A1 (en) 1997-09-24 1999-03-24 Guy A. Rouleau Allelic variants of the phospholipase c-gamma1 gene associated with bipolar disorder
CN1281335A (zh) 1997-10-27 2001-01-24 科泰克斯药物股份有限公司 用安哌克和精神安定剂治疗精神分裂症
TR200003525T2 (tr) 1998-05-29 2001-04-20 Eli Lilly And Company Bipolar bozuklukların tedavisi için kombinasyon terapisi
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
EP1165836A2 (de) 1999-03-30 2002-01-02 Genset Gene, proteine und biallelische markers die mit der schizophrenie assoziert sind
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US6239162B1 (en) 1999-05-17 2001-05-29 St. Elizabeth's Medical Center Method for treating depression
WO2002057790A2 (en) 2001-01-19 2002-07-25 Mindsense Biosystems Ltd. Methods and compositions for diagnosing and treating a subject having depression
EP1233075A3 (de) 2001-02-15 2003-01-08 Whitehead Institute For Biomedical Research BDNF Polymorphismus und Vereinigung mit doppelpoliger Geistesgestörtheit
JP2005503120A (ja) 2001-03-27 2005-02-03 マサチューセッツ　インスティテュート　オブ　テクノロジー Ｆｇｆダイマー化に関する方法及び生成物
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002083877A1 (en) 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20030096264A1 (en) 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20030152972A1 (en) 2001-11-08 2003-08-14 Whitehead Institute For Biomedical Research Gene expression associated with psychiatric disorders
US20030175253A1 (en) 2001-11-09 2003-09-18 Huda Akil Compositions and methods for diagnosing and treating mental disorders
US20040152107A1 (en) 2002-09-18 2004-08-05 C. Anthony Altar Gene signature of electroshock therapy and methods of use
AU2003291720A1 (en) 2002-11-01 2004-06-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
EP1560933A4 (de) 2002-11-14 2007-11-21 Wyeth Corp Verfahren und zusammensetzungen zur behandlung neurologischer erkrankungen
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
JP2007526898A (ja) 2003-08-07 2007-09-20 エンカム ファーマシューティカルズ アクティーゼルスカブ Ｌｐａを含む化合物
US20050209181A1 (en) 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
JP2005312435A (ja) 2004-03-29 2005-11-10 Kazuhito Rokutan うつ病の評価方法
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
CA2704428C (en) 2007-11-02 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Fgf9-related methods for treating anxiety
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
EP2453024A3 (de) 2012-08-15
AU2005258161B2 (en) 2011-05-26
EP2453024A2 (de) 2012-05-16
WO2006002262A3 (en) 2007-06-14
EP1766077A2 (de) 2007-03-28
US9486499B2 (en) 2016-11-08
WO2006002262A2 (en) 2006-01-05
US20140073568A1 (en) 2014-03-13
ES2660765T3 (es) 2018-03-26
CA2571243A1 (en) 2006-01-05
US9957568B2 (en) 2018-05-01
EP2453024B1 (de) 2017-12-06
US20170211144A1 (en) 2017-07-27
DK2453024T3 (en) 2018-02-12
US8415298B2 (en) 2013-04-09
DK1766077T3 (da) 2012-07-16
EP1766077B1 (de) 2012-03-28
US20060051786A1 (en) 2006-03-09
EP1766077A4 (de) 2008-02-13
AU2005258161A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
ATE551432T1 (de) Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
DE602005013811D1 (de) Behandlung von fettsucht und verbundenen erkrankungen
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE551350T1 (de) Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MX2010002674A (es) Moduladores de gamma secretasa.
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
MX2010005028A (es) Moduladores de gamma secretasa.
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
GB0425625D0 (en) Treatment of disease
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
WO2006135694A3 (en) Uii-modulating compounds and their use
ATE511401T1 (de) Kombinierte gentherapie zur behandlung makroskopischer glioma
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
WO2008125902A8 (en) Peripheral and neural inflammatory crosstalk